小剂量氨磺必利配合氯氮平治疗难治性精神分裂症效果分析
|
摘要
目的探讨对难治性精神分裂症患者选择小剂量氨磺必利+氯氮平药物治疗后获得的临床效果。方法选择该院2016年5月—2018年6月收治的74例难治性精神分裂症患者作为实验对象;抽签法分组后明确各组所用药物;对照组(37例):选择氯氮平+安慰剂药物展开疾病治疗;观察组(37例):选择小剂量氨磺必利+氯氮平药物展开疾病治疗;对比用药效果以及用药副反应。结果观察组痊愈患者23例(62.16%),显效患者9例(24.32%),有效患者4例(10.81%),无效患者1例(2.70%),愈显患者32例(86.49%),总有效患者36例(97.30%),对照组痊愈患者8例(21.62%),显效患者12例(32.43%),有效患者8例(21.62%),无效患者9例(24.32%),愈显患者20例(54.05%),总有效患者28例(75.68%),同对照组难治性精神分裂症患者用药效果(54.05%)、(75.68%)对比,观察组愈显率(86.49%)、总有效率(97.30%)提升程度明显(χ~2=9.314 7,7.400 0,P<0.05);同对照组难治性精神分裂症患者用药不良反应(29.73%)对比,观察组总发生率(35.14%)差异无统计学意义(χ~2=0.246 7,P>0.05)。结论难治性精神分裂症患者在接受治疗期间,小剂量氨磺必利+氯氮平的有效应用,同氯氮平+安慰剂用药效果比较,不会导致用药副反应增加,并且可使得临床治疗愈显率、总有效率明显提升,最终为难治性精神分裂症患者病情显著好转,奠定基础。
Objective To investigate the clinical effects of lowdose amisulpride + clozapine in patients with refractory schizophrenia.Methods Seventyfour patients with refractory schizophrenia admitted to our hospital from May 2016 to June 2018 were selected as subjects. The drugs used in each group were identified by grouping. The control group(37 cases): clozapine + placebo drugs for disease treatment; observation group(37 cases): choose a small dose of amisulpride + clozapine for disease treatment; compare drug use and drug side effects. Results In the observation group, 23 patients(62.16%) were cured, 9 patients(24.32%) were effective, 4 patients(10.81%) were effective, 1 patient(2.70%) was ineffective, and 32 patients(86.49%) were more effective. There were 36 patients(97.30%) with total effective disease, 8 patients(21.62%) with recovery in the control group, 12 patients(32.43%) with markedly effective disease, 8 patients(21.62%) with effective disease, and 9 patients(24.32%) with ineffective patients. 20 patients(54.05%),total effective patients 28 cases(75.68%), compared with the control group refractory schizophrenia patients(54.05%),(75.68%), the observation rate of the observation group(86.49%) and the total effective rate(97.30%) was significantly increased(χ~2=9.314 7, 7.400 0,P<0.05); compared with the control group refractory schizophrenia patients with drug side effects(29.73%), the total incidence of observation group(35.14%) There was no significant difference(χ~2=0.246 7,P>0.05). Conclusion The effective use of lowdose amisulpride + clozapine during refractory schizophrenia patients does not lead to an increase in side effects compared with clozapine plus placebo. The clinical treatment rate and the total effective rate were significantly improved, and finally the patients with refractory schizophrenia improved significantly and laid the foundation.
Objective To investigate the clinical effects of lowdose amisulpride + clozapine in patients with refractory schizophrenia.Methods Seventyfour patients with refractory schizophrenia admitted to our hospital from May 2016 to June 2018 were selected as subjects. The drugs used in each group were identified by grouping. The control group(37 cases): clozapine + placebo drugs for disease treatment; observation group(37 cases): choose a small dose of amisulpride + clozapine for disease treatment; compare drug use and drug side effects. Results In the observation group, 23 patients(62.16%) were cured, 9 patients(24.32%) were effective, 4 patients(10.81%) were effective, 1 patient(2.70%) was ineffective, and 32 patients(86.49%) were more effective. There were 36 patients(97.30%) with total effective disease, 8 patients(21.62%) with recovery in the control group, 12 patients(32.43%) with markedly effective disease, 8 patients(21.62%) with effective disease, and 9 patients(24.32%) with ineffective patients. 20 patients(54.05%),total effective patients 28 cases(75.68%), compared with the control group refractory schizophrenia patients(54.05%),(75.68%), the observation rate of the observation group(86.49%) and the total effective rate(97.30%) was significantly increased(χ~2=9.314 7, 7.400 0,P<0.05); compared with the control group refractory schizophrenia patients with drug side effects(29.73%), the total incidence of observation group(35.14%) There was no significant difference(χ~2=0.246 7,P>0.05). Conclusion The effective use of lowdose amisulpride + clozapine during refractory schizophrenia patients does not lead to an increase in side effects compared with clozapine plus placebo. The clinical treatment rate and the total effective rate were significantly improved, and finally the patients with refractory schizophrenia improved significantly and laid the foundation.
引文
[1]徐中利.奥氮平与氨磺必利联合用药方案治疗难治性精神分裂症的临床评价[J].中国医药指南,2018,16(29):30-31.
[2]崔文辉.抗精神病药物联合无抽搐电休克治疗难治性精神分裂症87例的疗效分析[J].中国实用医药,2018,13(24):86-87.
[3]白倩.氨磺必利联合MECT对难治性精神分裂症患者PNASS评分及生活质量的影响[J].现代诊断与治疗,2018,29(16):2558-2560.
[4]邹杨,左晓伟,周开矿.阿立哌唑联用小剂量氯氮平治疗女性难治性精神分裂症对照分析[J].系统医学,2018,3(16):42-44.
[5]李桦,吴荣琴,孙复林.无抽搐电休克维持治疗对难治性精神分裂症患者的疗效和认知功能的影响[J].临床精神医学杂志,2018,28(4):241-244.
[6]热娜古丽·艾买江,阿米娜·阿不都西库.无抽搐电休克治疗治疗难治性精神分裂症的临床效果观察[J].世界最新医学信息文摘,2018,18(67):63.
[7]马兆峰,庄晓华,何玲,等.利培酮联合氟西汀治疗难治性精神分裂症阴性症状的疗效、不良反应及对生活质量的影响[J].国际精神病学杂志,2018,45(3):462-464,479.
[8]蒋合萍,何玉华,刘君,等.熄风通窍中药联合银杏叶胶囊治疗难治性精神分裂症疗效及对认知功能、脑源性神经营养因子水平的影响[J].现代中西医结合杂志,2018,27(18):1992-1995.
[9]李启斌,陶领钢,石顺治,等.重复经颅磁刺激与无抽搐电休克联合利培酮治疗流浪难治性精神分裂症患者的临床对照研究[J].现代中西医结合杂志,2018,27(9):918-921,941.
[10]丁兆猛,陈振林.阿立哌唑联合氯氮平对难治性精神分裂症患者体质量指数、低密度脂蛋白胆固醇、总胆固醇水平的影响[J].实用临床医药杂志,2017,21(19):212.
[2]崔文辉.抗精神病药物联合无抽搐电休克治疗难治性精神分裂症87例的疗效分析[J].中国实用医药,2018,13(24):86-87.
[3]白倩.氨磺必利联合MECT对难治性精神分裂症患者PNASS评分及生活质量的影响[J].现代诊断与治疗,2018,29(16):2558-2560.
[4]邹杨,左晓伟,周开矿.阿立哌唑联用小剂量氯氮平治疗女性难治性精神分裂症对照分析[J].系统医学,2018,3(16):42-44.
[5]李桦,吴荣琴,孙复林.无抽搐电休克维持治疗对难治性精神分裂症患者的疗效和认知功能的影响[J].临床精神医学杂志,2018,28(4):241-244.
[6]热娜古丽·艾买江,阿米娜·阿不都西库.无抽搐电休克治疗治疗难治性精神分裂症的临床效果观察[J].世界最新医学信息文摘,2018,18(67):63.
[7]马兆峰,庄晓华,何玲,等.利培酮联合氟西汀治疗难治性精神分裂症阴性症状的疗效、不良反应及对生活质量的影响[J].国际精神病学杂志,2018,45(3):462-464,479.
[8]蒋合萍,何玉华,刘君,等.熄风通窍中药联合银杏叶胶囊治疗难治性精神分裂症疗效及对认知功能、脑源性神经营养因子水平的影响[J].现代中西医结合杂志,2018,27(18):1992-1995.
[9]李启斌,陶领钢,石顺治,等.重复经颅磁刺激与无抽搐电休克联合利培酮治疗流浪难治性精神分裂症患者的临床对照研究[J].现代中西医结合杂志,2018,27(9):918-921,941.
[10]丁兆猛,陈振林.阿立哌唑联合氯氮平对难治性精神分裂症患者体质量指数、低密度脂蛋白胆固醇、总胆固醇水平的影响[J].实用临床医药杂志,2017,21(19):212.